Hematopoietic Progenitor Kinase 1 Inhibitors
DOI:
https://doi.org/10.54097/kcpmqa71Keywords:
HPK1 inhibitors; tumor immunotherapy; SAR.Abstract
Cancer, a general name for wide range of diseases that have the ability to make an impact on any parts of the human body and has been a fatal health issue that affects people around the world. Hematopoietic Progenitor Kinase 1 (HPK1), one member from the MAP4K family, is a kind of serine/threonine kinase. Destruction of HPK1 kinase raises the secretion of cytokine and T cell signaling, having positive impact on clearance of virus, and inhibition of tumor growth. Thus, HPK1 has been seen as a promising target that can be used in drug development for immunotherapy of tumors. HPK1 has a pivotal role of inhibition on the signaling pathway of the T-cell receptor, it also inhibits the proliferation and differentiation of B cells, DC cells, and NK cells. In this paper, we aimed to supply a detailed overview of research including the introduction of HPK1, research process on HPK1 inhibitors and different methods of developing new kinase inhibitors.
Downloads
References
Bray, Freddie, et al. "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries." CA: a cancer journal for clinicians 68.6 (2018): 394-424.
Kim, Ryungsa. "Cancer immunoediting: from immune surveillance to immune escape." Cancer Immunotherapy (2007): 9-27.
Pan, Yang, et al. "RNA dysregulation: an expanding source of cancer immunotherapy targets." Trends in pharmacological sciences 42.4 (2021): 268-282.
Restifo, Nicholas P., Mark J. Smyth, and Alexandra Snyder. "Acquired resistance to immunotherapy and future challenges." Nature Reviews Cancer 16.2 (2016): 121-126.
Sharma, Padmanee, et al. "Primary, adaptive, and acquired resistance to cancer immunotherapy." Cell 168.4 (2017): 707-723.
Dhanak, Dashyant, et al. "Small-molecule targets in immuno-oncology." Cell chemical biology 24.9 (2017): 1148-1160.
Cheng, Binbin, et al. "Recent advances in small molecule-based cancer immunotherapy." European Journal of Medicinal Chemistry 157 (2018): 582-598.
Hernandez, Sairy, et al. "The kinase activity of hematopoietic progenitor kinase 1 is essential for the regulation of T cell function." Cell reports 25.1 (2018): 80-94.
Chuang, Huai-Chia, Xiaohong Wang, and Tse-Hua Tan. "MAP4K family kinases in immunity and inflammation." Advances in immunology 129 (2016): 277-314.
Zhu, Qiangsheng, et al. "Hematopoietic progenitor kinase 1 in tumor immunology: a medicinal chemistry perspective." Journal of Medicinal Chemistry 65.12 (2022): 8065-8090.
Wu, Ping, et al. "Hematopoietic progenitor kinase-1 structure in a domain-swapped dimer." Structure 27.1 (2019): 125-133.
Lau, Wai L., et al. "Using yeast surface display to engineer a soluble and crystallizable construct of hematopoietic progenitor kinase 1 (HPK1)." Acta Crystallographica Section F: Structural Biology Communications 77.1 (2021): 22-28.
Chuang, Huai-Chia, and Tse-Hua Tan. "MAP4K family kinases and DUSP family phosphatases in T-cell signaling and systemic lupus erythematosus." Cells 8.11 (2019): 1433.
Delpire, Eric. "The mammalian family of sterile 20p-like protein kinases." Pflügers Archiv-European Journal of Physiology 458 (2009): 953-967.
“Safety and Efficacy Study of CFI-402411 in Subjects with Advanced Solid Malignancies - Full Text View - ClinicalTrials.gov.” Clinicaltrials.gov, classic.clinicaltrials.gov/ct2/show/NCT04521413. Accessed 30 Sept. 2023.
Study of NDI 1150-101 in Patients with Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT05128487?cond=HPK1&draw=1&rank=10 (accessed September 24, 2023).
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT05315167?cond=HPK1&draw=1&rank=7 (accessed September 24, 2023)
BGB-15025 Alone and in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants with Advanced Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT04649385 (accessed September 24, 2023)
PF-07265028 As Single Agent and In Combination with Sasanlimab in Advanced or Metastatic Solid Tumors. https://www.clinicaltrials.gov/ct2/show/NCT05233436?cond=HPK1&draw=2&rank=5 (accessed September 24, 2023)
A Phase I Study of RGT-264 in Subjects with Advanced Solid Tumors. https://www.clinicaltrials.gov/ct2/show/NCT05764915?term=HPK1&cond=HPK1&draw=2&rank=5 (accessed September 24, 2023)
UNIVERSITY HEALTH NETWORK. Compiler: WO2016205942A1[P]. 2016-12-29.
Toure, Momar, et al. "Discovery of quinazoline HPK1 inhibitors with high cellular potency." Bioorganic & Medicinal Chemistry 92 (2023): 117423.
Wang, Beilei, et al. "An overview of kinase downregulators and recent advances in discovery approaches." Signal Transduction and Targeted Therapy 6.1 (2021): 423.
" What is allosteric inhibitor? ". www.globecancer.com http://www.globecancer.com/azzx/show.php?itemid=14419#:~:text=%E5%88%AB%E6%9E%84%E6%8A%91%E5%88%B6%E5%89%82%E5%8F%88%E5%8F%AB%E5%8F%98 [Accessed 23 Sep. 2023].
Wang, Weixue, et al. "Discovery of an allosteric, inactive conformation-selective inhibitor of full-length HPK1 utilizing a kinase cascade assay." Biochemistry 60.41 (2021): 3114-3124..
Qi, Si-Min, et al. "PROTAC: an effective targeted protein degradation strategy for cancer therapy." Frontiers in Pharmacology 12 (2021): 692574.
" PROTACs and Molecular Glues. ". www.astrazeneca.com https://www.astrazeneca.com/r-d/next-generation-therapeutics/protacs.html.
" PROTAC Technology: tool for new therapies development. " https://www.drugtimes.cn/2021/08/28/xinyaoyanfaliqiprotacjishuzuiquanjiedu/
Si, Jingwen, et al. "Hematopoietic progenitor kinase1 (HPK1) mediates T cell dysfunction and is a druggable target for T cell-based immunotherapies." Cancer Cell 38.4 (2020): 551-566.
Dale, Brandon, et al. "Advancing targeted protein degradation for cancer therapy." Nature Reviews Cancer 21.10 (2021): 638-654.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
